Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.

Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy. The purpose of the analysis was to evaluate outcomes of VTE management in cancer patients treated with rivaroxaban compared to enoxaparin. Methods This single-center retrospective analysis was conducted on patients with malignancy-associated VTE initiated on treatment with either rivaroxaban or enoxaparin.

Prophylaxis against venous thromboembolism in hospitalized medically ill patients: Update and practical approach.

Purpose: Major updates in the medical literature for the prevention of venous thromboembolism (VTE) in medically ill patients are reviewed. A suggested approach for risk assessment is provided along with a brief review of chemical prophylaxis use in special populations of the hospitalized medically ill.

Summary: Despite new and updated guidelines, the assessment of risk for both thrombosis and bleeding in medical patients continues to lack valid standardization.